Tela Bio Inc. (TELA)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
TELA Bio, Inc. (TELA) Q3 2025 Earnings Call Transcript
TELA Bio, Inc. ( TELA ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Antony Koblish - Co-founder, CEO & Director Jeffrey Blizard - President of TELA Bio & Director Roberto Cuca - CFO & COO Jim Hagen Conference Call Participants Louisa Smith - Gilmartin Group LLC Caitlin Cronin - Canaccord Genuity Corp., Research Division Frank Takkinen - Lake Street Capital Markets, LLC, Research Division Michael Sarcone - Jefferies LLC, Research Division Samantha Munoz Presentation Operator Good afternoon, ladies and gentlemen, and welcome to the TELA Bio Third Quarter 2025 Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded.
TELA Bio, Inc. (TELA) Reports Q3 Loss, Misses Revenue Estimates
TELA Bio, Inc. (TELA) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.42 per share a year ago.
TELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue Estimates
TELA Bio, Inc. (TELA) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.51 per share a year ago.
Tela Bio Inc. (TELA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Tela Bio Inc. ever had a stock split?
Tela Bio Inc. Profile
| Health Care Equipment & Supplies Industry | Healthcare Sector | Antony Koblish CEO | NASDAQ (NMS) Exchange | 872381108 CUSIP |
| US Country | 209 Employees | - Last Dividend | - Last Split | 8 Nov 2019 IPO Date |
Overview
TELA Bio, Inc. is a commercial-stage medical technology company dedicated to innovating soft-tissue reconstruction solutions that aim to improve clinical outcomes while respecting the patient's anatomy. Established in 2012 and based in Malvern, Pennsylvania, the company targets improving surgical procedures, particularly in the realms of hernia repair, abdominal wall reconstructions, and plastic and reconstructive surgery. TELA Bio has placed emphasis on utilizing a direct sales force to market its products, predominantly within the United States, thereby ensuring a focused and specialized approach towards addressing the needs of its clientele.
Products and Services
TELA Bio has developed a comprehensive portfolio of products designed to meet the diverse needs in soft-tissue reconstruction:
- OviTex Reinforced Tissue Matrix: This product range is designed for hernia repair and abdominal wall reconstructions. OviTex combines the natural benefits of biological tissue with the strength of synthetic materials, offering a unique solution for these complex procedures. The aim is to provide surgeons with a durable, yet biocompatible option that promotes more natural tissue integration.
- OviTex PRS Reinforced Tissue Matrix: Specifically tailored for plastic and reconstructive surgery, this product line seeks to address the unmet needs in this specialty. By focusing on the unique requirements of reconstructive surgeries, OviTex PRS provides a reinforced tissue matrix that supports the body's natural healing and tissue integration processes, facilitating better outcomes in a range of reconstructive procedures.
- OviTex for Laparoscopic and Robotic Procedures: This sterile reinforced tissue matrix is derived from ovine rumen and combined with polypropylene fiber. It is specially designed for use in laparoscopic and robotic-assisted hernia surgical repairs. The innovation lies in its adaptability to minimally invasive surgical techniques, thus offering patients the benefits of shorter recovery times and less post-operative discomfort, while maintaining the strength and reliability needed in hernia repairs.
Contact Information
